ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 21, 2025 19:00 ET | Source: ArriVent BioPharma, Inc. Exclusive global…
EPAM Completes Strategic Acquisition of First Derivative, Enhancing AI and Data-Driven Solutions for Financial Services
Strategic acquisition strengthens EPAM's financial services delivery capabilities in North America, Europe…
